Dr. Oh on Pacritinib in Myelofibrosis

Video

In Partnership With:

Stephen T. Oh, MD, PhD, discusses the benefits of pacritinib in patients with myelofibrosis.

Stephen T. Oh, MD, PhD, co-chief, Division of Hematology, associate professor, Department of Medicine, Hematology Division, associate professor, Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, discusses the benefits of pacritinib (Vonjo) in patients with myelofibrosis.

The primary analysis of the phase 3 PERSIST-2 study (NCT02055781) showed that patients treated with pacritinib were more likely to experience clinical improvement in hemoglobin compared with those who received best available therapy (BAT), Oh says. Although the primary analysis did not report the degrees of anemia response and transfusion independence, updated findings from this trial included transfusion independence rates in patients who received the 200 mg FDA-approved dose of pacritinib vs those treated with BAT, Oh explains.

In this analysis, pacritinib elicited a superior transfusion independence rate over BAT, at 24% vs 5% per SIMPLIFY criteria and 37% vs 7% per Gale criteria, Oh concludes.

Funding supported by CTI Biopharma. Content independently developed by OncLive

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,